Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema

Release Date:

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.

Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema

Title
Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
Copyright
Release Date

flashback